Rapport Therapeutics, INC Form 4 insider transactions

Rapport Therapeutics CEO Abraham Ceesay sold a total of 10,916 shares of common stock through pre-arranged trading plans.

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock on January 15, 2026, under a pre-arranged 10b5-1 trading plan.

Rapport Therapeutics' Chief Scientific Officer, David Bredt, reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Rapport Therapeutics' Chief Development Officer, Yeleswaram Krishnaswamy, reported the vesting of 9,000 performance-based restricted stock units and the subsequent sale of 2,840 shares to cover tax obligations.

Rapport Therapeutics CEO Abraham Ceesay executed sales of company common stock totaling approximately $323,588 through pre-arranged 10b5-1 trading plans.

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold a total of 8,500 shares of common stock on December 15, 2025, through a pre-arranged 10b5-1 trading plan.

Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, exercised stock options and immediately sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

Rapport Therapeutics CEO Abraham Ceesay disclosed modest open-market sales executed under a pre-set Rule 10b5-1 plan, while retaining a substantial stake.

Rapport Therapeutics’ Chief Scientific Officer David Bredt sold 8,500 shares on November 17, 2025 under a pre-set Rule 10b5-1 trading plan, retaining 401,142 shares.

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Rapport Therapeutics CEO Abraham Ceesay sold 10,916 shares of common stock for approximately $281,930 through pre-arranged 10b5-1 trading plans.

Rapport Therapeutics, Inc. CEO Abraham Ceesay reported the sale of 76,420 shares of common stock for approximately $2.01 million through pre-arranged 10b5-1 trading plans.

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock through a pre-arranged 10b5-1 trading plan.

Rapport Therapeutics Director Reid M. Huber purchased 20,400 shares, indicating insider confidence.

Rapport Therapeutics Director Steven M. Paul increased his indirect beneficial ownership by acquiring 41,666 shares of common stock through Paul Capital Strategy III Fund LLC.

Rapport Therapeutics Director Wendy B. Young acquired 3,500 shares of common stock at $22.60 per share, increasing her beneficial ownership.

Rapport Therapeutics' Chief Operating Officer, Cheryl Gault, executed a pre-planned sale of 5,000 common shares following the exercise of stock options.

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock for approximately $127,000 through a pre-arranged 10b5-1 trading plan.

Rapport Therapeutics' Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock for approximately $13.9955 per share as part of a pre-established Rule 10b5-1 trading plan.

Rapport Therapeutics, Inc. Director Ramiro Sanchez was granted 10,925 stock options with an exercise price of $10.95, vesting over one year or upon the next annual meeting.

Rapport Therapeutics, Inc. Director Wendy B. Young was granted 10,925 stock options with an exercise price of $10.95, vesting based on continued service.

Rapport Therapeutics, Inc. Director John Maraganore has been granted 21,850 stock options with an exercise price of $10.95, aligning his interests with the company's future performance.

Rapport Therapeutics, Inc. Director James Healy has been granted 21,850 stock options with an exercise price of $10.95, vesting based on continued service.

Rapport Therapeutics, Inc. Director Robert J. Perez was granted 10,925 stock options with an exercise price of $10.95, vesting over the next year, as disclosed in a recent SEC Form 4 filing.

Rapport Therapeutics, Inc. Director Reid M. Huber was granted 21,850 stock options with an exercise price of $10.95, vesting upon the earlier of June 17, 2026, or the next Annual Meeting of Stockholders.

Rapport Therapeutics, Inc. Director Steven M. Paul was granted 21,850 stock options with an exercise price of $10.95 per share, vesting upon specific conditions.

Rapport Therapeutics, Inc.'s Chief Scientific Officer, David Bredt, sold 8,500 shares of common stock for approximately $93,522 under a pre-arranged Rule 10b5-1 trading plan.

Rapport Therapeutics, Inc. Director Paul M. Silva was granted 10,925 stock options with an exercise price of $10.95, aligning his interests with shareholders.

David Bredt, Chief Scientific Officer of Rapport Therapeutics, sold 8,500 shares of common stock at an average price of $9.5602 under a pre-arranged 10b5-1 trading plan.

David Bredt, Chief Scientific Officer of Rapport Therapeutics, sold 8,500 shares of common stock on April 15, 2025, under a pre-arranged Rule 10b5-1 trading plan.